COVID-19 in breast cancer patients : a subanalysis of the OnCovid registry
© The Author(s), 2021..
BACKGROUND: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients.
METHODS: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population.
RESULTS: We included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (n = 245, 49.5%) and 177 (35.8%) had metastatic disease. A total of 332 (67.1%) patients were receiving active treatment, with radical intent in 232 (47.6%) of them. Hospitalization rate was 58.2% and all-cause mortality rate was 20.3%. One hundred twenty-nine (26.1%) patients developed one COVID-19 complication, being acute respiratory failure the most common (n = 74, 15.0%). In the multivariable analysis, age older than 70 years, presence of COVID-19 complications, and metastatic disease were factors correlated with worse outcomes, while ongoing anticancer therapy at time of COVID-19 diagnosis appeared to be a protective factor. No particular oncological treatment was related to higher risk of complications. In the context of SARS-CoV-2 infection, 73 (18.3%) patients had some kind of modification on their oncologic treatment. At the first oncological reassessment (median time: 46.9 days ± 36.7), 255 (51.6%) patients reported to be fully recovered from the infection. There were 39 patients (7.9%) with long-term SARS-CoV-2-related complications.
CONCLUSION: In the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Therapeutic advances in medical oncology - 13(2021) vom: 10., Seite 17588359211053416 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
Date Revised 04.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/17588359211053416 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333153340 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333153340 | ||
| 003 | DE-627 | ||
| 005 | 20240404232935.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/17588359211053416 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM333153340 | ||
| 035 | |a (NLM)34777582 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Garrigós, Laia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 in breast cancer patients |b a subanalysis of the OnCovid registry |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2021. | ||
| 520 | |a BACKGROUND: Cancer patients are at higher risk of COVID-19 complications and mortality than the rest of the population. Breast cancer patients seem to have better prognosis when infected by SARS-CoV-2 than other cancer patients | ||
| 520 | |a METHODS: We report a subanalysis of the OnCovid study providing more detailed information in the breast cancer population | ||
| 520 | |a RESULTS: We included 495 breast cancer patients with a SARS-CoV-2 infection. Mean age was 62.6 years; 31.5% presented more than one comorbidity. The most frequent breast cancer subtype was luminal-like (n = 245, 49.5%) and 177 (35.8%) had metastatic disease. A total of 332 (67.1%) patients were receiving active treatment, with radical intent in 232 (47.6%) of them. Hospitalization rate was 58.2% and all-cause mortality rate was 20.3%. One hundred twenty-nine (26.1%) patients developed one COVID-19 complication, being acute respiratory failure the most common (n = 74, 15.0%). In the multivariable analysis, age older than 70 years, presence of COVID-19 complications, and metastatic disease were factors correlated with worse outcomes, while ongoing anticancer therapy at time of COVID-19 diagnosis appeared to be a protective factor. No particular oncological treatment was related to higher risk of complications. In the context of SARS-CoV-2 infection, 73 (18.3%) patients had some kind of modification on their oncologic treatment. At the first oncological reassessment (median time: 46.9 days ± 36.7), 255 (51.6%) patients reported to be fully recovered from the infection. There were 39 patients (7.9%) with long-term SARS-CoV-2-related complications | ||
| 520 | |a CONCLUSION: In the context of COVID-19, our data confirm that breast cancer patients appear to have lower complications and mortality rate than expected in other cancer populations. Most breast cancer patients can be safely treated for their neoplasm during SARS-CoV-2 pandemic. Oncological treatment has no impact on the risk of SARS-CoV-2 complications, and, especially in the curative setting, the treatment should be modified as little as possible | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 outcomes | |
| 650 | 4 | |a OnCovid | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a breast cancer | |
| 700 | 1 | |a Saura, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Vila, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Zambelli, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Bower, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Pistilli, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Lambertini, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Ottaviani, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Diamantis, Nikolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Lumsden, Ailsa |e verfasserin |4 aut | |
| 700 | 1 | |a Pernas, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Generali, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Seguí, Elia |e verfasserin |4 aut | |
| 700 | 1 | |a Viñas, Gemma |e verfasserin |4 aut | |
| 700 | 1 | |a Felip, Eudald |e verfasserin |4 aut | |
| 700 | 1 | |a Sanchez, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Rizzo, Gianpiero |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Cortellini, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Perone, Ylenia |e verfasserin |4 aut | |
| 700 | 1 | |a Chester, John |e verfasserin |4 aut | |
| 700 | 1 | |a Iglesias, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Betti, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Vincenzi, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Libertini, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzoni, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Zoratto, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Berardi, Rossana |e verfasserin |4 aut | |
| 700 | 1 | |a Guida, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Wuerstlein, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Loizidou, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Sharkey, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilar Company, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Matas, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Saggia, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Chiudinelli, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Colomba-Blameble, Emeline |e verfasserin |4 aut | |
| 700 | 1 | |a Galazi, Myria |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Uma |e verfasserin |4 aut | |
| 700 | 1 | |a Van Hemelrijck, Mieke |e verfasserin |4 aut | |
| 700 | 1 | |a Marin, Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Strina, Carla |e verfasserin |4 aut | |
| 700 | 1 | |a Prat, Aleix |e verfasserin |4 aut | |
| 700 | 1 | |a Pla, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Ciruelos, Eva Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Bertuzzi, Alexia |e verfasserin |4 aut | |
| 700 | 1 | |a Del Mastro, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Porzio, Giampiero |e verfasserin |4 aut | |
| 700 | 1 | |a Newsom-Davis, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Delany, Maria Belen |e verfasserin |4 aut | |
| 700 | 1 | |a Krengli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Fotia, Vittoria |e verfasserin |4 aut | |
| 700 | 1 | |a Viansone, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Chopra, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Romeo, Margarita |e verfasserin |4 aut | |
| 700 | 1 | |a Salazar, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Perez, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a d'Avanzo, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Franchi, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Milani, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Pommeret, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Tucci, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Pedrazzoli, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Harbeck, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrante, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Gennari, Alessandra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in medical oncology |d 2009 |g 13(2021) vom: 10., Seite 17588359211053416 |w (DE-627)NLM19877978X |x 1758-8340 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g day:10 |g pages:17588359211053416 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/17588359211053416 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |b 10 |h 17588359211053416 | ||